Molecular Identification and Inhibition of the Deoxygenation-Activated, Calcium-Permeable Cation Channel of The Sickle Erythrocyte, Psickle, a Novel Therapeutic Target for Treatment of Sickle Disease
Seth L. Alper, M.D., Ph.D.
Beth Israel Deaconess Medical Center
NRF2 Induction as Novel Treatment for Sickle Cell Disease
Jen-Tsan A. Chi, M.D., Ph.D. & Marilyn J. Telen, M.D.
Duke University
Genomic Approaches to Prevent Red Blood Cell Alloimmunization in Patients with Sickle Cell Disease
Stella T. Chou, M.D. & Connie M. Westhoff, Ph.D.
Children's Hospital of Philadelphia/New York Blood Center
Modeling Sickle Cell Anemia with Induced Pluripotent Stem Cells
George Q. Daley, M.D., Ph.D.
Children's Hospital Boston
Effects of the Adenosine 2A Receptor Agonist Regadenoson on Sickle Cell Vaso-occlusion and Inflammation
Joshua J. Field, M.D., MS & Jonathan Lindner, M.D.
The Medical College Of Wisconsin, Inc/ Oregon Health Sciences University
Nanoparticle-Mediated Correction of the Sickle Cell Disease Mutation
Peter M. Glazer, M.D., Ph.D.
Yale University
Reversal of Sickle Cell-Related Chronic Kidney Disease
Antonio Guasch, M.D. & Marianne E.M. Yee, M.D., M.Sc.
Emory University
Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease
Carolyn C. Hoppe, M.D., M.P.H.
Children's Hospital and Research Center Oakland
Preclinical Evaluation of Globin Gene Transfer in Mobilized SCD Patient CD34+ Cells
Michel Sadelain, M.D., Ph.D. & Patricia A. Shi, M.D., MS
Memorial Sloan-Kettering Cancer Center/New York Blood Center